- Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Key statistics
On Friday, Gritstone bio Inc (GRTS:NSQ) closed at 0.7366, 9.68% above its 52-week low of 0.6716, set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.746 |
---|---|
High | 0.7777 |
Low | 0.7088 |
Bid | 0.725 |
Offer | 0.74 |
Previous close | 0.7437 |
Average volume | 3.69m |
---|---|
Shares outstanding | 105.92m |
Free float | 103.48m |
P/E (TTM) | -- |
Market cap | 78.77m USD |
EPS (TTM) | -1.55 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼